CLL ASH 2024 Highlights

home / data-dialogue-with-the-oncology-brothers / cll-ash-2024-highlights

Rahul Gosain, MD, MBA; Rohit Gosain, MD, and John Allan, MD, analyze significant developments in chronic lymphocytic leukemia (CLL) treatment, including 5-year SEQUOIA trial outcomes, AMPLIFY survival data, sonrotoclax-zanubrutinib combination therapy, and the emerging role of CAR T-cell therapy, as presented at the 2024 American Society of Hematology (ASH) Annual Meeting.

EP. 1: SEQUOIA Trial: Updates from ASH 2024

Rahul Gosain, MD;Rohit Gosain, MD;John Allan, MD

December 21st 2024

Experts review the 5-year results of the phase 3 SEQUOIA trial evaluating treatment options for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma at the 66th American Society of Hematology Annual Meeting and Exposition 2024.

EP. 2: Exploring Updates on AMPLIFY at ASH 2024

Rahul Gosain, MD;Rohit Gosain, MD;John Allan, MD

January 3rd 2025

Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from the AMPLIFY trial.

EP. 3: Key Updates From the CELESTIAL Trial Presented at ASH 2024

Rahul Gosain, MD;Rohit Gosain, MD;John Allan, MD

January 10th 2025

Experts discuss the comparative efficacy of sonrotoclax plus zanubrutinib vs venetoclax in chronic lymphocytic leukemia treatment based on updates presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024.

EP. 4: TRANSCEND 004: Highlights from ASH 2024

Rahul Gosain, MD;Rohit Gosain, MD;John Allan, MD

January 17th 2025

Experts examine the potential role of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia treatment, incorporating new evidence presented at the 66th American Society of Hematology Annual Meeting and Exposition 2024.